Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025
Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Fineline Cube Dec 13, 2025
Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Fineline Cube Dec 13, 2025
Company Deals

SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility

Fineline Cube Feb 27, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...

Company Deals

Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization

Fineline Cube Feb 27, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...

Company Drug

Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review

Fineline Cube Feb 27, 2023

China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Jacobio Pharma Partners with WestChina-Frontier for Preclinical Safety Studies

Fineline Cube Feb 27, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a partnership agreement with compatriot firm WestChina-Frontier PharmaTech,...

Company Drug

Mabwell’s IL-11 Monoclonal Antibody 9MW3811 Approved for Australian Clinical Trial

Fineline Cube Feb 27, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving clinical trial approval from...

Company Drug

AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval

Fineline Cube Feb 27, 2023

UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at...

Company Deals

CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research

Fineline Cube Feb 27, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Deals

Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center

Fineline Cube Feb 27, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai...

Company Deals Digital

Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services

Fineline Cube Feb 24, 2023

Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed...

Company Drug

CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA

Fineline Cube Feb 24, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...

Company Deals

Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development

Fineline Cube Feb 24, 2023

Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...

Company Drug

CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs

Fineline Cube Feb 24, 2023

The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...

Company Drug

InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study

Fineline Cube Feb 24, 2023

China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...

Company Drug

Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials

Fineline Cube Feb 24, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...

Company Deals

Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration

Fineline Cube Feb 24, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China...

Company Medical Device

NMPA Approves STmed’s ECMO Product for Market

Fineline Cube Feb 24, 2023

The National Medical Products Administration (NMPA) has approved STmed Technology’s extracorporeal cardiopulmonary support auxiliary equipment...

Company Medical Device

Johnson & Johnson MedTech’s QDOT Catheter Approved in China for Atrial Fibrillation

Fineline Cube Feb 24, 2023

Johnson & Johnson MedTech’s next-generation QDOT micro diagnostic/ablation deflectable tip catheter, a disposable pressure monitoring...

Company Deals

Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto

Fineline Cube Feb 24, 2023

US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...

Company Deals

ConjuStar Peptide-Drug Conjugate Angel Financing

Fineline Cube Feb 24, 2023

Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...

Policy / Regulatory

Guangdong Adds Hospitals to GBA Drug and Device Green Channel

Fineline Cube Feb 23, 2023

The Health Commission of Guangdong Province (GDHC) has released a second list of designated medical...

Posts pagination

1 … 489 490 491 … 596

Recent updates

  • InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
  • Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
  • GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
  • B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.